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Women are underrepresented in cardiovascular studies, even as their preponderance in the aging population
steadily increases. Although concerns have been raised about the differential benefit of antiplatelet medications
for women, the propensity for increased bleeding among women has also been recognized. A better understand-
ing of the factors contributing to the observed sex-related differences in platelet biology is warranted. These fac-
tors include differences in the frequency and expression of genetic polymorphisms affecting platelet responsive-
ness to agonists (with and without antiplatelet therapies), which might be obtained through population-based
studies and in large controlled clinical trials; inflammatory marker levels and their influence on atherothrombotic
risk, and the role of specific hormones in mediating platelet activation and function. Knowledge gained about
these mechanistic factors might inform the development of sex-specific antithrombotic treatment regimens that
confer optimized safety and efficacy. (J Am Coll Cardiol 2012;59:891–900) © 2012 by the American College
of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.075Although randomized clinical trials have shown the benefit
of antiplatelet therapy for patients with cardiovascular dis-
ease, their findings cannot reliably be generalized to sub-
groups if not sufficiently represented in study populations.
Because women are underrepresented in cardiovascular
trials (1,2), sex differences in the response to antithrom-
botic therapies, in terms of thrombosis and bleeding
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structs in platelet biology into
safe and effective patient care.
Epidemiology of
Thrombotic Disorders
in Women
Ischemic heart disease and stroke
account for nearly 25% of all deaths
among women worldwide (3). In
the United States, coronary artery
disease (CAD) accounted for 15.6%
of deaths in women in 2007, and
cerebrovascular disease accounted
for another 6.7% (4). These athero-
thrombotic disorders also account
or substantial morbidity and resource use. In 2007, 607,000
merican women were hospitalized for CAD; among those,
early 1 million cardiac catheterization, percutaneous coronary
ntervention (PCI), stenting, or coronary artery bypass graft
rocedures were performed, and the average length of hospital stay
as 5.3 days for acute myocardial infarction (MI) alone (5).
nother 458,000 women were hospitalized for cerebrovascular
isease that same year, staying an average of 5.4 days in the
ospital (5).
The prevalence of these disorders in women varies greatly
ith age. As shown in Figure 1, the incidence of CAD,
troke, and peripheral artery disease all increase substantially
s women become older (6). In particular, the incidence of
AD more than triples around the time of menopause (4).
urther, given the longer life expectancy of women relative
o men worldwide (3), increasing proportions of the direct
nd indirect costs of CAD and cerebrovascular disease,
urrently estimated at $505 billion in the United States
lone (7), will occur among women.
ex Differences in Platelet Biology
latelet reactivity. Differences in platelet reactivity across
opulations have been described using several methods and
n response to varying stimuli (Fig. 2) (8). Platelets from
omen without CAD are more reactive than those of men
n response to standard concentrations of agonists such as
denosine diphosphate (ADP) (2 to 20 mol/l) and throm-
bin receptor agonist protein (50 mol/l) (9,10). One study
showed that the number of glycoprotein (GP) IIb/IIIa
receptors that could bind PAC-1 antibody in response to
ADP or thrombin receptor agonist protein stimulation was
50% to 80% greater in women than in men (10). Among
asymptomatic patients, platelets from women, in particular,
white women, bound more fibrinogen in response to low
and high concentrations of ADP and showed more spon-
taneous aggregation compared with men after adjustment
for risk factors such as smoking, hypertension, diabetes,
hyperlipidemia, and aspirin use (11). In a population-based
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
CAD  coronary artery
disease
CI  confidence interval
CRP  C-reactive protein
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous
coronary interventionstudy of asymptomatic, premenopausal women, high plate-let reactivity was associated with an increased risk of
downstream MI (2- to 3-fold increased risk compared with
those with normal platelet reactivity) (12). A recent study of
signaling proteomes in platelets showed significantly higher
levels of signaling cascade proteins expressed on platelets
from male versus female donors (13). Although this concept
warrants further investigation, these early results suggest
that sex-specific platelet proteomic signaling mechanisms
might contribute to differences in platelet reactivity and
outcome disparities between women and men.
GeneSTAR (Genetic Study of Aspirin Responsiveness,
which studied healthy men and women, also demonstrated
higher platelet reactivity among women compared with men
in response to varying concentrations of arachidonic acid,
ADP, or epinephrine after adjustment for age, risk factors,
race, menopausal status, and hormone therapy (14). How-
ever, after low-dose aspirin therapy, men and women
showed similar degrees of platelet inhibition in response to
arachidonic acid (Fig. 3). After aspirin therapy, women’s
platelets remained significantly more reactive than those of
men in response to collagen or ADP stimulation; for
example, platelet aggregation in response to 5 g/ml colla-
gen was 31.8% for women and 27.2% for men after aspirin
therapy (p  0.001), which, according to the investigators,
likely reflects “platelet activation pathways indirectly related
to cyclooxygenase-1” (14). In addition to platelet-related sex
differences, thromboelastography-based studies also show a
greater prothrombotic tendency (increased speed and
strength of platelet-fibrin clotting) among women com-
pared with men (15,16).
Inflammation. Activated platelets, through the release of
cytokines and immunomodulatory ligands, mediate an in-
flammatory response that further amplifies platelet response
and endothelial activation during plaque rupture (17). On
Figure 1 Incidence of Atherothrombotic Disease
in Women by Age Category
Data for coronary artery disease and stroke are from the Framingham original
and offspring cohort, and data on peripheral arterial disease are from the ARIC
(Atherosclerosis Risk In Communities) cohort (per 1,000 person-years) (6).
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adhesion of platelet receptors and integrins to von Wille-
brand factor and collagen in the subendothelium (18,19).
Activated platelets also release inflammatory factors, bind to
leukocytes to form platelet-leukocyte coaggregates, facilitate
the release of proinflammatory cytokines, and may promote
an inflammatory response within the vessel wall (19,20).
Among healthy postmenopausal women in the Women’s
Health Study, a higher C-reactive protein (CRP) level, the
most commonly studied marker of inflammation, indepen-
dently predicted the risk of cardiovascular death, nonfatal MI,
stroke, or need for coronary revascularization (relative risk: 1.5
for the highest quartile versus the lowest; 95% confidence
interval [CI]: 1.1 to 2.1) (21). Although the Cardiovascular
Figure 2 Platelet Responsiveness to Aspirin and Clopidogrel
Laboratory measurement of platelet responsiveness to aspirin (A) and clopidogrel
(aspirin); COX  cyclooxygenase; GP  glycoprotein; LTA  light transmittance ag
pholipase A2; PRP  platelet-rich plasma; TEG  thrombelastography; VASP  vas
mission from Gurbel et al. (8).Health Study showed that CRP added to risk prediction onlyfor intermediate-risk men, and not women (22), a recent
meta-analysis showed a risk ratio for CAD of 1.41 (95% CI:
1.13 to 1.75) among women in 5 studies whose CRP level was
3.0 mg/l versus 1.0 mg/l (23). Other inflammatory mark-
ers, such as leukocyte count and P-selectin expression, may be
higher among healthy women and predictive of future cardio-
vascular events (24,25).
Antiplatelet therapies have been associated with pleiotro-
pic anti-inflammatory effects beyond their direct platelet-
mediated effects (26). Aspirin showed synergistic effects
with statins in lowering CRP levels in a population-based,
longitudinal stroke study in which 50% of the participants
were women, and this synergy did not differ by sex (27).
Clopidogrel therapy was associated with reduced levels of
A  arachidonic acid; ADP  adenosine diphosphate; ASA  acetylsalicylic acid
etry; PFA  platelet function analyzer; PKA  protein kinase A; PLA2  phos-
or-stimulated phosphoprotein; Y  monoclonal antibodies. Reprinted with per-(B). A
gregom
odilatinflammatory markers, even after adjustment for sex, in 1
a
s
s
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50% of the participants were women, CRP levels increased
1 month after clopidogrel cessation without significant sex
differences (29). Whether greater reduction in inflammation
with newer, more potent antiplatelet agents can improve
clinical outcomes in women, men, or both, is worthy of
further investigation.
Role of hormones in platelet biology and inflammation.
Megakaryocytes and platelets express the estrogen receptor  (30)
nd androgen receptor (30,31), and platelet nitric oxide
ynthase release and thromboxane A2 generation can be
modulated by estrogens and/or androgens (31,32). In addi-
tion, transcripts from both estrogen receptor  and andro-
gen are upregulated during megakaryocyte differentiation
(31). Thus, genomic effects in megakaryocytes, signaling
properties in platelets, or both, might contribute to sex
differences in platelet function (31).
There is conflicting evidence of the effect of female
menstrual-cycle hormones on platelet biology. One study
reported that platelets bound more fibrinogen during the
luteal phase than the follicular phase, suggesting that
hormones may regulate platelet GP IIb/IIIa activation (11).
Platelet adhesion to vascular collagen also demonstrates
biphasic peaks during the menstrual cycle (30). In contrast,
other studies found no significant relationship between
platelet aggregability and menstrual cycle phase, oral con-
traceptive use, or menopausal state (13,33,34). Both oral
contraceptive and perimenopausal hormonal agents alter
expression of proteins in the coagulation-fibrinolytic path-
ways, increasing both factor VII levels and activity, promot-
ing fibrinogen binding to platelets, and increasing levels of
fibrinogen and plasminogen activator inhibitor-1 (35).
Figure 3 Platelet Aggregation
Before and After Aspirin Treatment
Decrease in mean platelet aggregation in platelet-rich plasma in response to
various concentrations of agonists after aspirin therapy in 1,282 apparently
healthy children of parents with early coronary artery disease. ADP  adeno-
sine diphosphate. Data from Becker et al. (14).These changes may contribute to increased thrombotic risk.Systemic inflammation also mediates the relationship
between hormones and atherothrombotic risk. Randomized
(36) and cross-sectional (37) studies have found increased
CRP levels among post-menopausal women treated with
estrogen. However, in a nested case-control analysis from
the 2 randomized, controlled studies of the Women’s
Health Initiative, baseline CRP did not show a significant
statistical interaction with hormone therapy in predicting
CAD risk (38).
Several studies have suggested a link between genetic
polymorphisms for platelet glycoproteins and the risk of
atherothrombotic events (39–41), but relatively little is
known about whether sex-specific differences influence the
impact of these polymorphisms on platelet biology, treat-
ment response, and patient outcomes. Among women
receiving placebo in the HERS (Heart Estrogen–Progestin
Study), heterozygotes and homozygotes for the GP Ib-5C
allele had a significantly higher incidence of the composite
endpoint (death, MI, or unstable angina) at 5.8 years of
follow-up compared with women homozygous for the GP
Ib-5T allele (42). Postmenopausal hormone treatment was
associated with a 46% lower adjusted cardiovascular risk in
women with the -5C allele versus the -5TT genotype (p 
0.001 for interaction) (42). Hormone therapy was associated
with significant harm in the 21.2% of women who had the
GP Ib-TT and GP VI-TC/CC genotypes, and with
ignificant benefit in the 16.6% of women with the GP Ib
TC/CC and GP VI-TT genotypes (42). These data suggest
a role for pharmacogenomic testing in determining under-
lying cardiovascular risk in postmenopausal women, which
could alter the risk-benefit ratio for proposed antiplatelet
treatment. Further investigation is warranted, however.
Clinical Evidence of Sex Differences
in Response to Antiplatelet Therapy
Aspirin. In a meta-analysis of 6 randomized primary pre-
vention trials, aspirin therapy was associated with signifi-
cantly reduced stroke risk in the 51,342 women studied over
a mean 6.4 years of follow-up, but no significant effect was
shown for MI (43). In contrast, for men, MI risk was
significantly reduced with aspirin therapy, but no effect was seen
for stroke. (Tests for heterogeneity of treatment effect were
not reported.) The ATT (Antithrombotic Trialists) Collab-
oration meta-analysis noted significant reductions in major
coronary events and serious vascular events with aspirin
therapy in men, but not women, in both primary and
secondary prevention studies (Fig. 4) (44). After adjustment
for multiple comparisons, however, no heterogeneity of
treatment effect was noted by sex for any of the endpoints
assessed (44). The ISIS-2 (International Study of Infarct
Survival-2) trial likewise found that the reduction in vascu-
lar mortality with aspirin versus placebo therapy after acute
MI was 22% for men, but only 16% for women (p  0.05
for heterogeneity) (45).
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no clear overall benefit with aspirin doses 100 mg
compared with lower doses (46 – 48). Further, although
women have been shown to demonstrate higher platelet
reactivity (9,10,11,14), these secondary studies found no
particular benefit associated with a higher aspirin dose
among women. Based on sex differences in the epidemi-
ology of cardiovascular disease and available evidence
supporting therapy, the U.S. Preventive Services Task
Force recommends low-dose aspirin for the prevention of
MI among men age 45 to 79 years and for prevention of
stroke among women age 55 to 79 years, when the
potential benefit outweighs the potential risk of gastro-
Figure 4 Selected Outcomes in Primary and Secondary Prevent
CI  confidence interval. Reprinted with permission from the ATT (Antithrombotic Tintestinal bleeding (49).Similarly, the American Stroke Association and Ameri-
can Heart Association recommend aspirin therapy for per-
sons whose 10-year cardiovascular risk is at least 6% (50).
Thienopyridines. In a meta-analysis of 5 large random-
ized, controlled trials, clopidogrel treatment was associated
with a significant reduction in the risk of cardiovascular
events (cardiovascular death, MI, or stroke) overall in
patients with known risk factors for CAD (51). However,
among the 23,533 women evaluated, only the risk of MI
was significantly reduced with clopidogrel (relative risk:
0.81; 95% CI: 0.70 to 0.93) and not that for stroke or
all-cause mortality. (The 56,091 men evaluated showed
significant reductions in all 3 endpoints.) In the pivotal
rials of Aspirin, by Sex
s) Collaboration (44).ion T
rialistrandomized trials of the antiplatelet agents prasugrel (52)
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primary endpoint were relatively smaller in women than
in men, neither study noted a significant interaction
between sex and treatment assignment. Of note, these
studies were not powered to examine treatment interac-
tions among subgroups.
Polymorphisms of the cytochrome P450 (CYP) 2C19
allele have been independently associated with variable
responses to clopidogrel, specifically, clopidogrel prodrug
metabolism to its active metabolite. Higher risks of both
major bleeding (54) and stent thrombosis (55) have been
observed, depending on the presence of a gain-of-function
and loss-of-function genotype, respectively. Because these
polymorphisms are similarly distributed among men and
women, genotype-driven differences in outcome between
men and women would not be expected. However, studies
of this question could be important because other gene-gene
or gene-environment interactions might drive possible sex
differences.
GP IIb/IIIa inhibitors. A significant interaction between
reatment and sex was observed for trials of GP IIb/IIIa
nhibitors with respect to cardiovascular events. Although
P IIb/IIIa inhibitor use was associated with a significantly
educed incidence of death or MI at 30 days versus placebo
mong men with acute coronary syndromes (ACS), women
ad worse outcomes with such treatment (Table 1) (56).
Important differences in clinical characteristics may explain
this difference in treatment effect—women were older, had
more comorbid conditions, and more frequently had larger
infarctions compared with men. When risk was further
stratified by troponin level, no sex differences were seen.
More recent studies have not shown sex-related differences
in outcome, possibly because of the concomitant use of
clopidogrel (57).
Sex Differences in Bleeding
Associated With Antiplatelet Therapies
The Women’s Health Study reported that serious gastroin-
testinal bleeding requiring transfusion occurred more com-
monly among women randomized to receive aspirin for
Meta-Analysis of 6 Trials of GPI in Acute Coronary Syndromes: OutTable 1 Meta-Analysis of 6 Trials of GPI in Acute Coronary Syn
Women
GPI Control
Overall n  6,410 n  4,603
Death 3.9% 3.6% 1
Death or MI 11.5% 10.4% 1
Baseline cardiac troponin I or T 0.1 g/l n  1,548 n  1,003
Death 2.3% 2.0% 1
Death or MI 6.2% 5.3% 1
Baseline cardiac troponin I or T 0.1 g/l n  939 n  567
Death 6.2% 7.6% 0
Death or MI 12.7% 13.6% 0†For heterogeneity. Adapted with permission from Boersma et al. (56).
CI  confidence interval; GPI  GP IIb/IIIa inhibitor; MI  myocardial infarction; OR  odds ratio.primary prevention of cardiovascular disease versus placebo
(relative risk: 1.40; 95% CI: 1.07 to 1.83) (58). However, in
a meta-analysis by Berger et al. (43), aspirin use over an
average 6.4 years was associated with 2.5 major bleeding
events per 1,000 women treated versus 3 major bleeding
events per 1,000 men treated. For clopidogrel treatment, the
odds ratio for bleeding was numerically higher among
women than men (1.43; 95% CI: 1.15 to 1.79 vs. 1.22; 95%
CI: 1.05 to 1.42), but there was no evidence of heteroge-
neity of effect between women and men for major bleeding
(p  0.24) (43).
In ACS, sex-related differences in bleeding risk are
consistently demonstrated. In a multivariable risk model,
Subherwal et al. (59) identified sex as an independent
predictor of in-hospital major bleeding (odds ratio: 1.31;
95% CI: 1.23 to 1.39) among patients with ACS. In the
CRUSADE (Can Rapid risk stratification of Unstable
angina patients Suppress ADverse outcomes with Early
implementation of the ACC/AHA guidelines?) registry,
women who underwent invasive treatment with PCI had
significantly higher rates of in-hospital major bleeding
compared with men (14.1% vs. 5.9%, p  0.001) (60).
Women undergoing PCI tend to have more access-site
complications (e.g., access site bleeding, retroperitoneal
bleeding) (61), whereas gastrointestinal bleeding after MI
is more common in men (62). Bleeding-site differences
may relate in part to the smaller blood vessels in women
(63), but other sex-specific differences, such as in vascular
reactivity (64), might also contribute to differences in
bleeding risk. The question of weight-based dosing has
been raised for antiplatelet agents such as clopidogrel
(65), which might provide a mechanism for variations in
antiplatelet response, particularly among women with less
body mass.
The CRUSADE registry identified a significant interac-
tion between sex, GP IIb/IIIa inhibitor use, and bleeding
risk (p  0.014) (Fig. 5) (60). Some of the higher bleeding
risk in women receiving antithrombotic therapy reflects
inappropriate dosing of these agents. An estimated 15% of
the major bleeding observed in CRUSADE could be
s by Sexes: Outcomes by Sex
Men
p Value†5% CI)* GPI Control OR (95% CI)
n  11,886 n  8,502
.89–1.33) 3.2% 3.8% 0.83 (0.71–0.96) 0.030
.01–1.30) 10.4% 12.6% 0.81 (0.75–0.89) 0.001
n  2,095 n  1,449
.69–2.10) 2.3% 2.1% 1.07 (0.67–1.71) 0.84
.91–1.83) 7.6% 6.9% 1.10 (0.84–1.43) 0.65
n  2,174 n  1,284
.53–1.21) 4.1% 5.2% 0.75 (0.54–1.04) 0.88
.68–1.28) 9.3% 11.3% 0.82 (0.65–1.03) 0.48comedrom
OR (9
.08 (0
.15 (1
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molecular weight heparin, or GP IIb/IIIa inhibitors (66).
Even after adjustment for age, weight, and renal function,
women remained at higher risk of excess dosing and
bleeding than did men. Among women, excess dosing of
these agents accounted for 72% of the increased bleeding
risk compared with only 27% of the risk in men (60). In the
ISAR-REACT (Intracoronary Stenting and Antithrom-
botic Regimen: Rapid Early Action for Coronary Treatment)
(67) and ACUITY (Acute Catheterization and Urgent Inter-
vention Triage strategY) trials (68), rates of bleeding compli-
cations were also higher among women compared with men
receiving appropriately dosed bivalirudin.
Bleeding has implications beyond the event itself. Pa-
tients who have bleeding in the setting of ACS are more
likely to have a heightened systemic inflammatory response
(69) and are less likely to be prescribed antiplatelet therapies
at discharge (70), possibly because reinitiation of such
therapies is deferred until the patient is deemed “safe”
from additional bleeding. However, this treatment “gap”
can persist for as long as 6 months after the initial event
(70). Given the higher incidence of in-hospital bleeding
among women compared with men, this phenomenon
has major implications for their risk of future ischemic
events.
Implications and Knowledge Gaps
The cumulative evidence highlights a conundrum in which
women are at higher risk of both thrombosis and bleeding
compared with men (60). Excess antithrombotic drug dos-
ing, an important culprit, can be reduced by implementation
of quality-improvement measures (71), but sex differences in
bleeding risk persist even with appropriate dosing. These
Figure 5 Major Bleeding by Sex and GPI Dosing
Incidence of in-hospital major bleeding among women and men with acute cor-
onary syndromes who did not receive a GP IIb/IIIa inhibitor (GPI), those who
received appropriate GPI dosing, and those who received excess GPI dosing in
the CRUSADE registry. Probability values represent unadjusted comparisons.
Adapted with permission from Alexander et al. (60).differences might be explained by innate differences in mplatelet reactivity and contributing influences from inflam-
matory and hormonal processes, as outlined earlier. What,
then, can be done to reduce cardiovascular risk without
increasing bleeding risk?
One consideration might be the use of platelet function
testing or pharmacogenomics to guide drug selection and
dosing (72). The recent GRAVITAS (Gauging Respon-
siveness With A VerifyNow Assay-Impact On Thrombosis
And Safety) trial showed that women had significantly
higher residual platelet reactivity after standard clopidogrel
dosing compared with men when a point-of-care ADP-
specific platelet aggregation assay was used (72). However,
in this study, an empirical, higher clopidogrel dosing strat-
egy in response to platelet testing results did not improve
clinical outcomes (73). In contrast, a small study by Cuisset
et al. (74) found that patients with high platelet reactivity
while taking clopidogrel who were randomized to routine
(vs. provisional) GP IIb/IIIa inhibitor therapy during PCI
had improved 30-day cardiovascular event rates without a
significant increase in bleeding.
Sex-specific implications are difficult to draw from these
small studies. Targeting other platelet pathways might
present another therapeutic option. Cilostazol, which in-
creases intracellular cyclic adenosine monophosphate via
selective phosphodiesterase inhibition, has shown additional
platelet inhibition among patients with high on-treatment
reactivity to clopidogrel. Cilostazol, in addition to aspirin
and clopidogrel therapy, has reduced long-term cardiovas-
cular risk without an increase in bleeding among patients
undergoing PCI (75) and has shown substantial benefit
among women that has not been observed among men (76).
lthough tailored therapy is an attractive concept, the lack
f an accepted standardized test and uncertainty about
lternative therapeutic options to optimize outcomes cur-
ently limits recommendations for the use of these tests in
outine practice (77).
A systematic knowledge gap exists regarding sex differ-
nces in platelet biology, genomics, and response to thera-
eutics. Women remain underrepresented in both early and
ater phase studies (2). One reason may reflect their pre-
onderance in older populations, which are underrepre-
ented by approximately 50% relative to their prevalence in
he general ACS population alone (78), when not excluded
rom research altogether (79). It could also reflect physician
nderestimation of risk, misinterpretation of symptoms, and
ias against referral for interventional treatment of cardio-
ascular disease in women (80). Finally, women who are
andidates for inclusion in cardiovascular trials might be less
illing than men to participate because of a greater per-
eived risk of harm and adverse events (81).
Although higher baseline levels of platelet reactivity have
een observed in women, we are in need of a better
nderstanding of the responsible factors, including the
elative frequency and expression of genetic polymorphisms
ffecting platelet responsiveness, differences in inflammatory
arker levels and their influence on atherothrombotic risk,
33
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These mechanistic underpinnings will form the basis of
sex-specific treatment regimens aimed at optimizing the
safety and efficacy of antithrombotic therapy. Analyses of
sex-specific differences can provide insight into the scientific
basis for individual therapy differences and provide future
directions for research. Dedicated trial designs for genetic,
in vitro, and clinical studies are needed to balance female
representation in platelet-related research.
Conclusions
Although it has been known for decades that women
respond differently from men to antithrombotic therapies—
showing a greater propensity for bleeding, even with appro-
priate dosing, and differential benefit in terms of prevention
of ischemic events—only a minority of comparative studies
have provided insights into the biology underlying sex-
related differences in platelet function and response. It is
imperative for the scientific community to embark on
carefully designed investigations to fill an existing knowl-
edge gap that affects patient care.
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